SABSW · As filed with the SEC
SAB Biotherapeutics cash flow statement, by fiscal year
The statement as SAB Biotherapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net income (loss) | 13,273,683 | (34,105,309) | (42,193,786) | (18,740,804) |
| Gain on debt extinguishment of Paycheck Protection Program SBA Loan | — | — | — | 0 |
| Depreciation and amortization | 2,994,763 | 4,705,771 | 3,653,151 | 3,169,429 |
| Amortization of right-of-use assets | — | — | — | 122,449 |
| Amortization of finance right-of-use assets | 86,823 | 86,824 | 92,131 | — |
| Stock-based compensation expense | 5,210,647 | 2,941,796 | 2,423,720 | 2,674,203 |
| Gain on sale of equipment | — | — | 44,493 | (15,805) |
| Gain on partial lease termination | — | — | — | (32,208) |
| Loss on private placement issuance | — | — | 3,402,784 | — |
| Gain from private placement warrant termination | — | — | (3,572,920) | — |
| Net realized and unrealized gain on investment in short-term securities | (73,967) | — | — | — |
| Changes in fair value of warrant liabilities | (62,754,186) | (5,385,009) | 4,823,237 | (10,399,200) |
| Accretion of discounts on short-term investments | (88,631) | (237,093) | — | — |
| Professional fees settled with equity instruments | — | — | 3,881,566 | — |
| Write-off of deferred issuance costs | 261,105 | — | — | — |
| Changes in operating assets and liabilities | ||||
| Accrued interest receivable | (891,826) | (54,955) | — | — |
| Accounts receivable | — | — | 5,556,577 | 2,454,131 |
| Prepaid expenses | — | — | (523,610) | 674,552 |
| Operating lease right-of-use assets | — | — | — | 53,441 |
| Operating lease right-of-use assets | — | — | 387,299 | — |
| Prepaid expenses and other current assets | (5,285,259) | (590,461) | — | — |
| Operating lease right-of-use assets and liabilities, net | 67,420 | (23,458) | — | — |
| Accounts payable | 1,482,793 | 923,323 | (2,701,720) | (779,425) |
| Due to related party | — | — | — | (2,367) |
| Deferred grant income | — | — | 1,322,410 | — |
| Deferred grant income | — | (1,322,410) | — | (100,000) |
| Accrued expense and other current liabilities | 941,524 | (1,231,028) | (1,714,737) | (2,537,907) |
| Net cash used in operating activities | (44,775,111) | (34,292,009) | (25,119,405) | (23,459,511) |
| Cash flows from investing activities: | ||||
| Proceeds from the sale of equipment | 500 | — | 44,450 | 76,390 |
| Purchases of equipment | (933,156) | (337,262) | (197,154) | (2,166,414) |
| Purchases of investment securities | (142,035,560) | (37,446,201) | — | — |
| Sales and maturities of investments | 21,262,086 | 25,821,196 | — | — |
| Net cash used in investing activities | (121,706,130) | (11,962,267) | (152,704) | (2,090,024) |
| Cash flows from financing activities: | ||||
| Proceeds from Business Combination, net of transaction costs | — | — | — | 0 |
| Proceeds from issuance of common stock | — | — | — | 7,680,799 |
| Proceeds from private placement issuance of preferred stock and warrants | — | — | 7,500,000 | — |
| Proceeds from exercise of private placement preferred warrants | — | — | 59,654,000 | — |
| Proceeds from the 2025 PIPE, net of Series B issuance costs | 168,729,827 | — | — | — |
| Payment of deferred issuance costs | (758) | (261,105) | — | — |
| Proceeds from issuance of notes payable | — | 515,986 | 765,194 | (1,236,125) |
| Payments of notes payable | — | — | (1,028,654) | — |
| Principal payments of notes payable | (275,849) | (1,290,982) | — | (2,260,183) |
| Payments related to the Forward Share Purchase Agreement | — | — | — | (5,521,246) |
| Principal payments on finance leases | (142,563) | (132,003) | (126,985) | (161,055) |
| Proceeds from exercise of stock options | — | 20,409 | 9,582 | 76,971 |
| Tax payments for share settlement of restricted stock units | (11,205) | (24,931) | — | — |
| Net cash provided by (used in) financing activities | 168,299,452 | (1,172,626) | 66,773,137 | 1,051,411 |
| Effect of exchange rate changes on cash and cash equivalents | (213,497) | (241,198) | 18,144 | — |
| Net increase (decrease) in cash and cash equivalents | 1,604,714 | (47,668,100) | 41,519,172 | (24,498,124) |
| Cash and cash equivalents | ||||
| Beginning of period | 8,897,966 | 56,566,066 | 15,046,894 | 39,545,018 |
| End of period | 10,502,680 | 8,897,966 | 56,566,066 | 15,046,894 |
| Supplemental cash flow information: | ||||
| Cash paid for interest | 242,032 | 373,954 | 245,481 | — |
| Supplemental information on non-cash investing and finance activities: | ||||
| Right-of-use assets obtained in exchange for operating lease liabilities | 2,422,191 | 368,425 | 993,811 | — |
| Settlement of accrued liabilities through the issuance of common stock | — | — | 1,500,000 | — |
| Issuance of common stock for prepaid marketing and investor related consulting services | — | — | 240,000 | — |
| Fair value of private placement preferred warrant liability associated with warrant exercise | — | — | 699,795 | — |
| Deferred issuance costs included in accrued expenses | 149,387 | — | — | — |
| Reclassification of warrants from liability to equity | 90,691,094 | — | — | — |
| Reclassification of Redeemable Preferred Stock to Permanent Equity upon Requisite Approval | 16,038,660 | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.